Personalized and precision medicine (PPM) - the targeting of therapies according to an individual's genetic, environmental, or lifestyle characteristics - is becoming an increasingly important approach in health care treatment and prevention. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding of the requisite underlying research; and it examines recent empirical applications of PPM.

Intro; Contents; Acknowledgment; Introduction / Ernst R. Berndt, Dana P. Goldman, and John W. Rowe; 1. The Economic Value and Pricing of Personalized Medicine / Tomas J. Philipson; 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS / Manuel Hermosilla and Jorge Lemus; 3. The Value of Pharmacogenomic Information / John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson; 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory / Ernst R. Berndt and Mark R. Trusheim. 5. Characterizing the Drug Development Pipeline for Precision Medicines / Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern6. Cost Sharing in Insurance Coverage for Precision Medicine / Mark V. Pauly; 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments / Kristopher J. Hult; 8. Physicians' Financial Incentives to Personalize Medicine / David H. Howard, Jason Hockenberry, and Guy David 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan / Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger / Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright; 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies / Philippe Gorry and Diego Useche ContributorsAuthor Index; Subject Index